Pharmacokinetics and safety of agomelatine in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with Major Depressive Disorder. An open-labelled, multicenter, three-dose level, non-comparative study.
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2018
Price : $35 *
At a glance
- Drugs Agomelatine (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors IRIS
- 27 Sep 2018 This trial has been completed in Estonia.
- 19 Feb 2013 New trial record